IRA im­pact: As­traZeneca and Mer­ck CEOs warn of on­col­o­gy drug de­vel­op­ment shifts

This lat­est quar­ter­ly earn­ings sea­son for phar­ma has been a time for com­pa­nies to vent about Pres­i­dent Biden’s new drug price ne­go­ti­a­tion law, with some com­pa­nies like Al­ny­lam point­ing to or­phan drug des­ig­na­tion re­stric­tions, and oth­ers like Eli Lil­ly not­ing the dis­par­i­ties be­tween small and large mol­e­cule drugs when it comes to when the ne­go­ti­a­tions kick off (9 years vs. 13 years).

But As­traZeneca and Mer­ck ex­ec­u­tives are now rais­ing con­cerns about how the IRA will im­pact can­cer drug de­vel­op­ment mov­ing for­ward as the clock for ne­go­ti­a­tions be­gins with the first ap­proved in­di­ca­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER